504 related articles for article (PubMed ID: 31862336)
1. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Wang TF; Milligan PE; Wong CA; Deal EN; Thoelke MS; Gage BF
Thromb Haemost; 2014 Jan; 111(1):88-93. PubMed ID: 24136071
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF;
Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820
[TBL] [Abstract][Full Text] [Related]
5. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
Chan KE; Thadhani RI; Maddux FW
Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.
Joy M; Tharp E; Hartman H; Schepcoff S; Cortes J; Sieg A; Mariski M; Lee Y; Murphy M; Ranjbar G; Sharaf S; Yau G; Choi HA; Samuel S
Pharmacotherapy; 2016 Jul; 36(7):740-8. PubMed ID: 27265806
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effectiveness of venous thromboembolism prophylaxis with enoxaparin between obese and non-obese patients.
Alnatsheh AH; Beckett RD; Waterman S
J Oncol Pharm Pract; 2019 Jun; 25(4):813-817. PubMed ID: 29486637
[TBL] [Abstract][Full Text] [Related]
9. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
[TBL] [Abstract][Full Text] [Related]
10. Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Olson EJ; Bandle J; Calvo RY; Shackford SR; Dunne CE; Van Gent JM; Zander AL; Sikand H; Bongiovanni MS; Sise MJ; Sise CB
J Trauma Acute Care Surg; 2015 Dec; 79(6):961-8; discussion 968-9. PubMed ID: 26317819
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Migita K; Bito S; Nakamura M; Miyata S; Saito M; Kakizaki H; Nakayama Y; Matsusita T; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Saisho K; Miyahara H; Segata T; Nakagawa Y; Kamei M; Torigoshi T; Motokawa S
Arthritis Res Ther; 2014 Jul; 16(4):R154. PubMed ID: 25047862
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients.
Lee YR; Blanco DD
J Thromb Thrombolysis; 2017 Oct; 44(3):386-391. PubMed ID: 28828713
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy.
Brunetti L; Wassef A; Sadek R; Deshpande K; Ziegler J; Na SS; Riley P; Kagan L
Surg Obes Relat Dis; 2019 Mar; 15(3):363-373. PubMed ID: 30713119
[TBL] [Abstract][Full Text] [Related]
14. Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Elsaid KA; Collins CM
Am J Health Syst Pharm; 2012 Mar; 69(5):390-6. PubMed ID: 22345418
[TBL] [Abstract][Full Text] [Related]
15. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Walker CK; Sandmann EA; Horyna TJ; Gales MA
Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
17. Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: An observational study.
Patanwala AE; Seaman SM; Kopp BJ; Erstad BL
Thromb Res; 2018 Sep; 169():152-156. PubMed ID: 30071480
[TBL] [Abstract][Full Text] [Related]
18. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
19. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
20. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
